- Home
- SAN vs GILD Comparison
SAN vs GILD Comparison
Compare SAN & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAN
- GILD
- Stock Information
- Founded
- SAN 1857
- GILD 1987
- Country
- SAN Spain
- GILD United States
- Employees
- SAN N/A
- GILD N/A
- Industry
- SAN Commercial Banks
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SAN Finance
- GILD Health Care
- Exchange
- SAN Nasdaq
- GILD Nasdaq
- Market Cap
- SAN 112.2B
- GILD 129.9B
- IPO Year
- SAN 1987
- GILD 1992
- Fundamental
- Price
- SAN $7.42
- GILD $96.91
- Analyst Decision
- SAN
- GILD Buy
- Analyst Count
- SAN 0
- GILD 25
- Target Price
- SAN N/A
- GILD $109.00
- AVG Volume (30 Days)
- SAN 5.0M
- GILD 8.8M
- Earning Date
- SAN 04-30-2025
- GILD 04-24-2025
- Dividend Yield
- SAN 2.86%
- GILD 3.26%
- EPS Growth
- SAN 20.30
- GILD 1118.07
- EPS
- SAN 0.87
- GILD 4.73
- Revenue
- SAN $54,835,711,180.00
- GILD $28,735,000,000.00
- Revenue This Year
- SAN $23.59
- GILD $1.88
- Revenue Next Year
- SAN $2.50
- GILD $3.95
- P/E Ratio
- SAN $8.28
- GILD $20.49
- Revenue Growth
- SAN 6.36
- GILD 4.68
- 52 Week Low
- SAN $4.27
- GILD $62.07
- 52 Week High
- SAN $7.46
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- SAN 64.04
- GILD 34.47
- Support Level
- SAN $7.14
- GILD $95.30
- Resistance Level
- SAN $7.46
- GILD $107.17
- Average True Range (ATR)
- SAN 0.10
- GILD 3.66
- MACD
- SAN 0.02
- GILD -0.73
- Stochastic Oscillator
- SAN 91.41
- GILD 24.95
About SAN Banco Santander S.A. Sponsored ADR (Spain)
Santander's focus is on retail and commercial banking. Latin America is geographically the most significant operation, with Brazil making the largest contribution. Its continental European business is mainly in Spain and Portugal. Santander's UK presence is the result of its acquisition of Abbey building society. In the US, Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).